Equity Overview
Price & Market Data
Price: $0.264
Daily Change: -$0.0215 / 8.14%
Range: $0.26 - $0.282
Market Cap: $4,547,769
Volume: 542,126
Performance Metrics
1 Week: -4.03%
1 Month: -5.07%
3 Months: -26.03%
6 Months: -46.23%
1 Year: -94.13%
YTD: -37.96%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.